Charlotte Allerton is Head of Medicine Design at Pfizer, leading the scientific disciplines of Medicinal Chemistry, Pharmacokinetics, Dynamics and Metabolism (PDM), and Discovery Sciences, and enabling a deep focus on the design and delivery of small-molecule medicines across Pfizer’s therapeutic areas.
Charlotte joined the Medicinal Chemistry team at Pfizer, U.K. in 1993 and spent 14 years working across a range of therapeutic areas, including a secondment to Japan. In 2007, Charlotte joined PDM, progressing to lead the U.K. group, and then in 2010, she took on leadership of the Pre-Clinical Sciences team for Pain Research. In 2012, Charlotte moved to the U.S. to lead small molecule PDM and, in 2016, expanded her responsibilities to lead Medicine Design. During her tenure, Charlotte has worked with numerous teams to build a strong pipeline of small molecule therapeutics across Neuroscience, Rare Disease, Inflammation and Immunology, Internal Medicine, Oncology, and Antivirals, moving multiple new molecular entities into clinical development and to regulatory approval.
Charlotte obtained her BSc from the University of Nottingham and MPhil in organic chemistry from the University of Cambridge.